ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model. [electronic resource]
Producer: 20200113Description: 432-444 p. digitalISSN:- 1528-0020
- Animals
- Biomarkers, Tumor
- Cell Cycle Checkpoints -- genetics
- Cell Line, Tumor
- Cell Survival -- drug effects
- DNA Methylation
- Disease Models, Animal
- Epigenesis, Genetic
- Humans
- Immunoconjugates -- administration & dosage
- Leukemia, Lymphocytic, Chronic, B-Cell -- drug therapy
- Mice
- MicroRNAs -- administration & dosage
- Nanoparticles -- administration & dosage
- Receptor Tyrosine Kinase-like Orphan Receptors -- antagonists & inhibitors
- Survival Rate
- Theranostic Nanomedicine
- Treatment Outcome
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.